Development of SARS-CoV-2 antibody test technologies suitable for on-site diagnosis

This proposal aims to develop essential technologies for rapid and accurate SARS-CoV-2 antibody test in serum and droplet blood using microflow cytometry immunoassay (MCIA) for on-site testing. The test will assess levels of immunoglobin G (IgG) and immunoglobin M (IgM) antibodies produced in response to SARS-CoV-2 exposure. Unfortunately, none of the antibody testing tools currently available are suited for rapid and accurate on-site testing. The proposed MICA antibody test would serve as a much-needed on-site test method of infection and immunity screening. The developed antibody testing can change the game in the fight against COVID-19. The proposed MCIA antibody test is a revolutionary new tool that offers faster and more accurate SARS-CoV-2 infection and immunity testing compared to existing methods, providing on-site test results within mere minutes, completely altering the trajectory of the COVID-19 pandemic.

Faculty Supervisor:

Chang-Qing Xu

Student:

Jianxi Qu;Yushan Zhang;Tyler Kashak

Partner:

Forsee Instruments

Discipline:

Engineering

Sector:

Manufacturing

University:

McMaster University